Pharma-Q Bupivacaine Injection 50 mg/10 ml Solution for injection
PDF Leaflet Revision Date: 08 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Used for peripheral nerve block, caudal or epidural block.
Dosage (summary)
Max 150 mg per injection; 2 mg/kg body mass.
Onset of Action / Duration
Onset: Rapid, Duration: Up to 8 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
- Pregnant women
Pregnancy & Breastfeeding
Use in pregnancy not established; minimal risk in breastfeeding.
Key Drug Interactions
- Amiodarone
- Propranolol
- Calcium-channel blockers
Contraindications
- Hypersensitivity to bupivacaine
- Intravenous regional anaesthesia
- Active CNS disease
- Coagulation disorders
Common side effects
- Bradycardia
- Hypotension
- Nausea
- Urinary retention
Counselling Points
- Avoid driving until effects are known.
- Monitor for signs of toxicity.
- Resuscitative equipment must be available.
Serious warnings
- Cardiac arrest risk
- CNS toxicity
- Hypotension during epidural anaesthesia
Important Disclaimer
The Pharma-Q Bupivacaine Injection 50 mg/10 ml Solution for injection professional information leaflet below is the property of Pharma-Q Holdings and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
